详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Efficacy of surgery and adjuvant therapy in older patients with colorectal cancer: a STROBE-compliant article.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Institute of Digestive Surgery and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China [2]Department of Oncology and Department of Clinical and Experiment Medicine, Linköping University, Linköping, Sweden [3]Department of Surgery in Östergötland, Norrköping, Sweden [4]Department of Pathology, Jönköping Hospital, Jönköping, Sweden [5]Department of General Surgery, Shanghai First People's Hospital, Shanghai Jiaotong University, Shanghai, China

出处：

DOI：

ISSN：

摘要：

The present study aimed to assess the efficacy of surgery and adjuvant therapy in older patients (age≥70 years) with colorectal cancer (CRC). Older CRC patients are under-represented in available clinical trials, and therefore their outcomes after receiving surgery and adjuvant therapy are unclear. From two prospective Swedish databases, we assessed a cohort of 1021 patients who underwent curative surgery for stage I, II, or III primary CRC, with or without adjuvant chemotherapy/radiotherapy. Of the patients with colon cancer (n=467), 182 (39%) were aged <70 years, 162 (35%) aged 70 to 80 years, and 123 (26%) were aged ≥80 years. Of rectal cancer patients (n=554), 264 (48%) were aged <70 years, 234 (42%) aged 70 to 80 years, and 56 (10%) aged ≥80 years. Older patients with either colon or rectal cancer had higher comorbidity than did younger patients. Older patients with colon cancer had equivalent postoperative morbidity and 30-day mortality to younger patients. Rectal cancer patients aged ≥80 years had a higher 30-day mortality than younger patients (odds ratio [OR], 2.37; 95% confidence interval [CI], 1.6-4.55; P=0.03). For either colon or rectal cancer, adjuvant chemotherapy compromised the 5-year overall survival (OS) of older patients with stage II disease and had no effect on those with stage III disease. Receiving adjuvant chemotherapy was a poor factor of OS for older patients with either colon (HR 1.88, 95% CI: 1.20-4.35, P=0.03) or rectal cancer (HR 1.72, 95% CI: 1.05-2.26, P=0.004). Preoperative short-course radiotherapy improved both OS and local control for older patients with stage III rectal cancer and had no effect on those with stage II disease. Radiotherapy was a favorable factor for the OS of the older patients with rectal cancer (HR 0.42, 95% CI: 0.21-3.57, P=0.01). In conclusion, Older CRC patients had equal safety of surgery as younger patients, except rectal cancer patients aged ≥80 years that had a higher mortality. Adjuvant 5FU-based chemotherapy did not benefit older CRC patient, while neoadjuvant radiotherapy improved the prognosis of older patients with stage III rectal cancer.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2014]版：

大类 | 2 区医学

小类 | 2 区医学：内科

最新[2025]版：

大类 | 4 区医学

小类 | 4 区医学：内科

第一作者：

第一作者机构： [1]Institute of Digestive Surgery and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China

共同第一作者：

通讯作者：

通讯机构： [1]Institute of Digestive Surgery and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China [2]Department of Oncology and Department of Clinical and Experiment Medicine, Linköping University, Linköping, Sweden [*1]Department of Oncology and Department of Clinical and Experimental Medicine, Linko¨ping University, SE-581 85 Linko¨ping, Sweden [*2]Institute of Digestive Surgery and State key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

推荐引用方式(GB/T 7714)：

APA：

MLA：